

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

08 Jul 2026

### The effects of probiotic supplementation on oxidative indices in women with rheumatoid arthritis: a randomized controlled trial

#### Protocol summary

##### Summary

The present study is a double-blind, placebo-controlled, randomized trial to investigate the effect of probiotic supplementation on oxidative indices in women with rheumatoid arthritis. Sixty patients attending the rheumatology clinic of Sina hospital or Sheykholrayis clinic will be recruited and randomly assigned to receive either the intervention or the placebo. Inclusion criteria for the patients will be: 1) Patients diagnosed with rheumatoid arthritis, based on ACR criteria; 2) Having inactive to moderate rheumatoid arthritis; 3) Under treatment with DMARDs (Methotrexate, Hydroxychloroquine and Prednisolone less than 10 milligrams per day) and not receiving NSAIDs or cytokine inhibitors; 4) Stable medication for at least 3 month prior to the interventions; 5) Having body mass index (BMI) less than 40; 6) Willing to participate in the study; 7) Ages between 20 and 80. Exclusion criteria will include: 1) Pregnant and lactating women; 2) Hormone therapy or receiving oral contraceptives; 3) Having diabetes mellitus, thyroid disorders, kidney or hepatic diseases or Cushing's syndrome; 4) Having inflammatory bowel disease or other inflammatory disorders; 5) Having digestive tract disorders or lactose intolerance; 6) Taking antioxidant, vitamin, fiber or omega-3 supplements 3 weeks prior to the interventions; 7) Using antibiotics a month prior to the interventions; 8) Being on a weight reduction diet; 9) Smoking or being exposed to cigarette smoke; 10) Using other probiotic products. The intervention group will receive one 250 milligram capsule containing 10(10) colony forming unit (CFU) *Lactobacillus casei* each day, for 8 weeks; the other group will take one placebo capsule a day for the same period of time. At baseline and at the endpoint of the study, weight and height will be measured and BMI will be calculated; physical activity and psychological stress of the patients will be assessed using the relevant questionnaires and dietary intake of the participants will be evaluated by one 24 hour dietary recall questionnaire

and 3 dietary record questionnaires. The level of malondialdehyde and antioxidant enzymes including catalase, superoxide dismutase and glutathione peroxidase, as well as serum total antioxidant capacity will be measured using the appropriate techniques at baseline and endpoint of the study.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201207024105N10**

Registration date: **2012-07-05, 1391/04/15**

Registration timing: **prospective**

Last update:

Update count: **0**

##### Registration date

2012-07-05, 1391/04/15

##### Registrant information

##### Name

Beit Allah Alipour

##### Name of organization / entity

Health & Nutrition Faculty

##### Country

Iran (Islamic Republic of)

##### Phone

+98 41 1335 7580

##### Email address

alipourb@tbzmed.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Vice Chancellor of Research, Tabriz University of Medical Sciences

##### Expected recruitment start date

2012-08-31, 1391/06/10

**Expected recruitment end date**

2012-10-31, 1391/08/10

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

The effects of probiotic supplementation on oxidative indices in women with rheumatoid arthritis: a randomized controlled trial

**Public title**

The effects of probiotic supplementation on oxidative indices in women with rheumatoid arthritis

**Purpose**

Treatment

**Inclusion/Exclusion criteria**

Inclusion criteria: 1) Patients diagnosed with rheumatoid arthritis, based on ACR criteria; 2) Having inactive to moderate rheumatoid arthritis; 3) Under treatment with DMARDs (Methotrexate, Hydroxychloroquine and Prednisolone less than 10 milligrams per day) and not receiving NSAIDs or cytokine inhibitors; 4) Stable medication for at least 3 month prior to the interventions; 5) Having body mass index (BMI) less than 40; 6) Willing to participate in the study; 7) Ages between 20 and 80. Exclusion criteria: 1) Pregnant and lactating women; 2) Hormone therapy or receiving oral contraceptives; 3) Having diabetes mellitus, thyroid disorders, kidney or hepatic diseases or Cushing's syndrome; 4) Having inflammatory bowel disease or other inflammatory disorders; 5) Having digestive tract disorders or lactose intolerance; 6) Taking antioxidant, vitamin, fiber or omega-3 supplements 3 weeks prior to the interventions; 7) Using antibiotics a month prior to the interventions; 8) Being on a weight reduction diet; 9) Smoking or being exposed to cigarette smoke; 10) Using other probiotic products.

**Age**

From **20 years** old to **80 years** old

**Gender**

Female

**Phase**

2-3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Double blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Tabriz University of Medical Sciences

**Street address**

Golbad Avenue

**City**

Tabriz

**Postal code****Approval date**

2012-06-25, 1391/04/05

**Ethics committee reference number**

9150

**Health conditions studied****1****Description of health condition studied**

Rheumatoid Arthritis

**ICD-10 code**

M06.9

**ICD-10 code description**

Rheumatoid arthritis, unspecified

**Primary outcomes****1****Description**

Malondialdehyde

**Timepoint**

At baseline and after 8 weeks of intervention

**Method of measurement**

Spectrophotometry

**2****Description**

Catalase

**Timepoint**

At baseline and after 8 weeks of intervention

**Method of measurement**

Spectrophotometry

**3****Description**

Superoxide dismutase

**Timepoint**

At baseline and after 8 weeks of intervention

**Method of measurement**

Spectrophotometry

#### 4

**Description**

Glutathione peroxidase

**Timepoint**

At baseline and after 8 weeks of intervention

**Method of measurement**

Spectrophotometry

#### 5

**Description**

Serum total antioxidant capacity

**Timepoint**

At baseline and after 8 weeks of intervention

**Method of measurement**

Spectrophotometry

### Secondary outcomes

#### 1

**Description**

Body Mass Index (BMI)

**Timepoint**

At baseline and after 8 weeks of intervention

**Method of measurement**

Calculation based on the measured weight and height

#### 2

**Description**

Calorie and nutrient intake

**Timepoint**

At baseline and after 8 weeks of intervention

**Method of measurement**

One 24 hour dietary recall questionnaire and three dietary record questionnaires

### Intervention groups

#### 1

**Description**

One 250 milligram capsule containing 10(10) colony forming unit (CFU) Lactobacillus.casei each day, for 8 weeks

**Category**

Treatment - Drugs

#### 2

**Description**

One daily 250 milligram capsule not containing the probiotic bacteria for 8 weeks

**Category**

Placebo

### Recruitment centers

#### 1

**Recruitment center****Name of recruitment center**

Sina hospital

**Full name of responsible person****Street address****City**

Tabriz

#### 2

**Recruitment center****Name of recruitment center**

Sheykholyayis Clinic

**Full name of responsible person****Street address****City**

Tabriz

### Sponsors / Funding sources

#### 1

**Sponsor****Name of organization / entity**

Vice chancellor for Research, Tabriz University of Medical Sciences

**Full name of responsible person**

Mohammadreza Rashidi

**Street address**

Golbad Street

**City**

Tabriz

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice chancellor for Research, Tabriz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

*empty*

### Person responsible for general inquiries

**Contact**

### Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Elnaz Vaghef Mehrabany

**Position**

MSc student in nutrition sciences

**Other areas of specialty/work****Street address**

Attar neyshapoory Avenue, Golgasht Street

**City**

Tabriz

**Postal code****Phone**

+98 41 1335 7580

**Fax****Email**

elnaz.vaghef@gmail.com

**Web page address****Other areas of specialty/work****Street address**

Attar Neyshapoory Avenue, Golgasht Street

**City**

Tabriz

**Postal code****Phone**

+98 41 1335 7580

**Fax****Email**

elnaz.vaghef@gmail.com

**Web page address****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*

**Person responsible for updating data****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Elnaz Vaghef Mehrabany

**Position**

MSc student in nutrition sciences